Banco Bilbao Vizcaya Argentaria S.A. Reduces Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Banco Bilbao Vizcaya Argentaria S.A. decreased its holdings in Boston Scientific Co. (NYSE:BSX - Free Report) by 18.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 76,938 shares of the medical equipment provider's stock after selling 17,093 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.'s holdings in Boston Scientific were worth $6,873,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in BSX. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Boston Scientific by 0.6% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 2,620,372 shares of the medical equipment provider's stock valued at $234,052,000 after purchasing an additional 16,818 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Boston Scientific by 8.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,946,379 shares of the medical equipment provider's stock valued at $799,092,000 after acquiring an additional 695,000 shares in the last quarter. Dark Forest Capital Management LP boosted its holdings in Boston Scientific by 11.0% during the 4th quarter. Dark Forest Capital Management LP now owns 18,100 shares of the medical equipment provider's stock worth $1,617,000 after acquiring an additional 1,797 shares during the last quarter. Alta Advisers Ltd boosted its holdings in Boston Scientific by 23.9% during the 4th quarter. Alta Advisers Ltd now owns 4,832 shares of the medical equipment provider's stock worth $432,000 after acquiring an additional 932 shares during the last quarter. Finally, Fayez Sarofim & Co grew its stake in shares of Boston Scientific by 41.1% in the 4th quarter. Fayez Sarofim & Co now owns 5,351 shares of the medical equipment provider's stock worth $478,000 after acquiring an additional 1,558 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Analyst Ratings Changes

Several research firms recently weighed in on BSX. Stifel Nicolaus boosted their price target on shares of Boston Scientific from $100.00 to $115.00 and gave the stock a "buy" rating in a report on Thursday, February 6th. Piper Sandler boosted their target price on Boston Scientific from $95.00 to $115.00 and gave the stock an "overweight" rating in a research note on Monday, February 3rd. Royal Bank of Canada boosted their price objective on Boston Scientific from $116.00 to $120.00 and gave the stock an "outperform" rating in a research report on Thursday, April 24th. Argus set a $130.00 target price on Boston Scientific in a research note on Tuesday, February 18th. Finally, Wells Fargo & Company raised their price objective on shares of Boston Scientific from $100.00 to $118.00 and gave the stock an "overweight" rating in a report on Thursday, February 6th. One research analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Boston Scientific presently has a consensus rating of "Buy" and an average price target of $114.52.

Insiders Place Their Bets

In related news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the transaction, the executive vice president now owns 5,502 shares of the company's stock, valued at approximately $560,103.60. This trade represents a 75.88 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP John Bradley Sorenson sold 6,528 shares of Boston Scientific stock in a transaction on Friday, February 7th. The stock was sold at an average price of $104.97, for a total transaction of $685,244.16. Following the completion of the transaction, the executive vice president now owns 26,449 shares in the company, valued at approximately $2,776,351.53. The trade was a 19.80 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 138,009 shares of company stock valued at $14,407,381 over the last quarter. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Price Performance

Shares of Boston Scientific stock traded up $0.51 on Tuesday, hitting $102.69. 5,478,642 shares of the company traded hands, compared to its average volume of 6,347,135. Boston Scientific Co. has a 12-month low of $70.97 and a 12-month high of $107.17. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. The company has a market cap of $151.89 billion, a P/E ratio of 82.15, a P/E/G ratio of 2.79 and a beta of 0.73. The firm's 50-day simple moving average is $98.62 and its 200 day simple moving average is $95.03.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.08. The firm had revenue of $4.66 billion during the quarter, compared to analyst estimates of $4.57 billion. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The company's revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 earnings per share. Analysts expect that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.